Stifel raised the firm’s price target on C4 Therapeutics (CCCC) to $13 from $12 and keeps a Buy rating on the shares. The company’s Q4 update reiterated the timing of 2024 catalysts and extended its cash runway, the analyst tells investors. Throughout the first half of the year, commentary on enrollment pace and cohort opening related to its studies of CFT7455 in combination with dexamethasone will be important to assess the scope of the data update coming in the second half of 2024, the firm adds. Overall, investors will want a sample size that will be large enough for cross-trial comparison on the overall response rate to Bristol’s (BMY) mezigdomide.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- New Debt & Financing Risk for C4 Therapeutics, Inc. – What’s the Latest?
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics upgraded to Neutral from Underweight at JPMorgan
- C4 Therapeutics call volume above normal and directionally bullish
- C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
